| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000002068 |
| Receipt No. | R000002522 |
| Official scientific title of the study | Effectiveness of rebamipide for human gastric membrane after distal gastrectomy |
| Date of disclosure of the study information | 2009/06/11 |
| Last modified on | 2016/06/15 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Effectiveness of rebamipide for human gastric membrane after distal gastrectomy | |
| Title of the study (Brief title) | rebamipide trial for gastritis after distal gastrectomy | |
| Region |
|
|
| Condition | ||
| Condition | Gastritis in remnant stomach | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To avoid gastritis in remnant stomach, rebamipide will protect the inflammatory change of the membrane. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Patient number with gastritis or inflammatory change in remnant stomach |
| Key secondary outcomes | Loss of body weight |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | NO |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | Pseudo-randomization |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Rebamipide 300mg per day for a year | |
| Interventions/Control_2 | No treatment | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patient who underwent distal gastrectomy | |||
| Key exclusion criteria | 1.Patients treated with gastric secretion inhibitor in a month prior to this study.
2.Patients with thoracotomy, hepatectomy, pancreatomy or colectomy. 3.Patients with other malignancy. 4.Patients with cardiac, hepatic or hematologic disease. |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Hisahiro Matsubara |
| Organization | Chiba University Graduate School of Medicine |
| Division name | Frontier Surgery |
| Address | 1-8-1, Inohana, Chuouku,Chiba |
| TEL | 043-222-7171 |
| hk@faculty.chiba-u.jp | |
| Public contact | |
| Name of contact person | Hiroshi Kawahira |
| Organization | Chiba University Graduate School of Medicine |
| Division name | Frontier Surgery |
| Address | 1-8-1, Inohana, Chuouku,Chiba |
| TEL | 043-222-7171 |
| Homepage URL | |
| hk@faculty.chiba-u.jp | |
| Sponsor | |
| Institute | Chiba University Graduate School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Scholarship donation |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000002522 |